JP2009527479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009527479A5 JP2009527479A5 JP2008555401A JP2008555401A JP2009527479A5 JP 2009527479 A5 JP2009527479 A5 JP 2009527479A5 JP 2008555401 A JP2008555401 A JP 2008555401A JP 2008555401 A JP2008555401 A JP 2008555401A JP 2009527479 A5 JP2009527479 A5 JP 2009527479A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- alkoxy
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 229910052799 carbon Inorganic materials 0.000 claims 25
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 18
- -1 C 1 -C 5 alkoxy Chemical group 0.000 claims 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000006726 (C1-C5) alkenyl group Chemical group 0.000 claims 12
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000005309 thioalkoxy group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 150000004677 hydrates Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000002207 metabolite Substances 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 0 *CN(*)C(c1c(*)c(*)c(*)c(OC2C(*)(*)C(*)(*)N(*)C(*)(*)*2)c1*)=O Chemical compound *CN(*)C(c1c(*)c(*)c(*)c(OC2C(*)(*)C(*)(*)N(*)C(*)(*)*2)c1*)=O 0.000 description 6
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77497206P | 2006-02-17 | 2006-02-17 | |
| PCT/US2007/004247 WO2007098086A2 (en) | 2006-02-17 | 2007-02-16 | Hydroxypiperidine derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009527479A JP2009527479A (ja) | 2009-07-30 |
| JP2009527479A5 true JP2009527479A5 (enExample) | 2010-04-08 |
Family
ID=38437913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555401A Pending JP2009527479A (ja) | 2006-02-17 | 2007-02-16 | ヒドロキシピペリジン誘導体とその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20090036429A1 (enExample) |
| EP (1) | EP1991233A4 (enExample) |
| JP (1) | JP2009527479A (enExample) |
| WO (1) | WO2007098086A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| EP2141994A4 (en) * | 2007-04-26 | 2011-05-18 | Avalon Pharmaceuticals | POLYCYCLIC COMPOUNDS AND USES THEREOF |
| MX2010005298A (es) | 2007-11-16 | 2010-06-30 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. |
| EP2231666B1 (en) | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| AU2009240643B2 (en) | 2008-04-23 | 2014-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| PT2598483T (pt) | 2010-07-29 | 2020-10-12 | Rigel Pharmaceuticals Inc | Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos |
| JP6664632B2 (ja) * | 2013-09-30 | 2020-03-13 | 国立大学法人 東京大学 | アディポネクチン受容体活性化化合物 |
| US10112948B2 (en) * | 2015-07-06 | 2018-10-30 | The Board Of Regents Of The University Of Texas System | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers |
| JP7471818B2 (ja) | 2016-08-18 | 2024-04-22 | ヴィダック ファーマ リミテッド | ピペラジン誘導体、医薬組成物、及びその使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4263438A (en) * | 1977-09-13 | 1981-04-21 | Pfizer Inc. | 3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics |
| EP0641320B1 (en) * | 1991-04-17 | 2001-05-30 | PHARMACIA & UPJOHN COMPANY | Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists |
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| US5519134A (en) * | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| TR200102911T2 (tr) * | 1999-04-09 | 2002-01-21 | Astrazeneca Ab | Adamantan türevleri. |
| US7361666B2 (en) * | 1999-05-25 | 2008-04-22 | Sepracor, Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| JP2005538091A (ja) * | 2002-07-24 | 2005-12-15 | イーライ・リリー・アンド・カンパニー | ジヒドロ−ベンゾ［ｂ，ｅ］オキセピンに基づく選択的エストロゲン受容体調節物質、組成物および方法 |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US7094791B2 (en) * | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| CA2539361A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| BRPI0417156A (pt) * | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| EP2607362B1 (en) * | 2005-02-17 | 2014-12-31 | Astellas Pharma Inc. | Piperidine and piperazine carboxylates as FAAH inhibitors |
-
2007
- 2007-02-16 US US12/224,109 patent/US20090036429A1/en not_active Abandoned
- 2007-02-16 WO PCT/US2007/004247 patent/WO2007098086A2/en not_active Ceased
- 2007-02-16 EP EP07751036A patent/EP1991233A4/en not_active Withdrawn
- 2007-02-16 JP JP2008555401A patent/JP2009527479A/ja active Pending
-
2010
- 2010-07-21 US US12/804,449 patent/US20110178066A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009527479A5 (enExample) | ||
| CN101486703B (zh) | 一类具有抗肿瘤活性的黄酮化合物、其制备方法及其用途 | |
| JP2010527915A5 (enExample) | ||
| RU2009106214A (ru) | Ингибиторы ундекапренилпирофосфатсинтазы | |
| CN102993148B (zh) | 槲皮素衍生物或其类似物及其应用 | |
| JP2007511504A5 (enExample) | ||
| JP2010509379A5 (enExample) | ||
| JP2004528376A5 (enExample) | ||
| JP2015096525A5 (enExample) | ||
| NZ532494A (en) | Dibenzylamine compound and medicinal use thereof | |
| RU2008141151A (ru) | Производные n-гидроксилсульфонамида в качестве новых физиологически полезных доноров нитроксила | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| JP2006521335A5 (enExample) | ||
| JP2002513793A5 (enExample) | ||
| ZA200507933B (en) | Acetylene derivatives as inhibitors of histone deacetylase | |
| MX342806B (es) | Compuestos y método para reducir el ácido úrico. | |
| CR7612A (es) | Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2007532627A5 (enExample) | ||
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| JP2010535706A5 (enExample) | ||
| EP4225292A1 (en) | Truxillic acid monoester-derivatives as selective fabp5 inhibitors and pharmaceutical compositions and uses thereof | |
| BR0205683A (pt) | Processo para a preparação de derivados de piperazina, e, mesilato de um composto | |
| BR112012029033A2 (pt) | compostos | |
| Hou et al. | Synthesis and Structure‐Activity Relationships of A Novel Class of Dithiocarbamic Acid Esters as Anticancer Agent |